Key result
The CYP2C9 variant rs2860905 was strongly associated with warfarin sensitivity (<4 mg/day) among Caribbean Hispanics of Puerto Rico (OR 7.07).
Why the study?
Do specific genetic polymorphisms predict warfarin dose requirements in Caribbean Hispanics of Puerto Rico?
Case-Control (n=115)
Open-label
No
Do specific genetic polymorphisms predict warfarin dose requirements in Caribbean Hispanics of Puerto Rico?
Effect estimate: OR 7.07 (95% CI 3.33-15.03)
p-value: p=1.00 x 10^-6
Novel ethno-specific genetic variants, such as CYP2C9 rs2860905, significantly predict warfarin dose requirements in Caribbean Hispanics, highlighting the need for population-specific pharmacogenetic algorithms.
Supports ancestry-specific warfarin pharmacogenetics in Puerto Ricans; hypothesis-generating and requires prospective validation before practice change.
Existing algorithms account for ~50% of observed variance in warfarin dose requirements after including common polymorphisms. However, they do not perform as well in populations other than Caucasians, in part because some ethno-specific genetic variants are overlooked. The objective of the present study was to identify genetic polymorphisms that can explain variability in warfarin dose requirements among Caribbean Hispanics of Puerto Rico. Next-Generation Sequencing of candidate genes CYP2C9 and VKORC1 and genotyping by DMET® Plus Assay of 106 cardiovascular patients were performed. We also aimed at characterizing the genomic structure and admixture pattern of this study cohort. Our study used the Extreme Discordant Phenotype approach to perform a case-control association analysis. The CYP2C9 variant rs2860905, which was found in all the major haplotypes occurring in the Puerto Rican population, showed stronger association with warfarin sensitivity (A; CYP2C9 rs1856908; ABCB1 c.IVS9-44A>G/ rs10276036; CES2 c.269-965A>G/ rs4783745) and non-genetic factors (i.e., hypertension, diabetes and age) showed better prediction of warfarin dose requirements than CYP2C9*2 and CYP2C9*3 combined (partial R2=0.132 versus 0.023 and 0.007, respectively, p<0.001). The genetic background of Puerto Ricans in the study cohort showed a tri-hybrid admixture pattern, with a slightly higher than expected contribution of Native American ancestry (25%). The genomic diversity of Puerto Ricans is highlighted by the presence of 11 different major haplotype blocks in the CYP2C9 locus. Although our findings need further replication, this study contributes to the field by identifying novel genetic variants that increase predictability of stable warfarin dosing among Caribbean Hispanics.
No takes yet. Share an insight, caveat, or question.
Claudio‐Campos et al. (2017) conducted a case-control in Thromboembolic disorders requiring warfarin (n=115). CYP2C9 rs2860905 variant vs. Non-carriers was evaluated on Warfarin sensitivity (<4 mg/day) (OR 7.07, 95% CI 3.33-15.03, p=1.00 x 10^-6). The CYP2C9 variant rs2860905 was strongly associated with warfarin sensitivity (<4 mg/day) among Caribbean Hispanics of Puerto Rico (OR 7.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: